We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Charles River Stock Surges 102.3% in a Year: What's Fueling the Drive?
Read MoreHide Full Article
Key Takeaways
CRL stock surged 102.3% in a year, outperforming the industry's 7.5% and the S&P 500's 11.3% gain.
CRL's DSA bookings jumped 32% to $652 million in Q3 2026, while backlog rose to $2.03 billion.
CRL projects a 1.5-2.0% revenue decline in 2026, despite organic growth expectations of at least 1.5%.
Charles River Laboratories International (CRL - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 102.3%, outperforming the industry’s 7.5% growth. The S&P 500 composite has increased 11.3% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Charles River is a full-service, early-stage contract research organization, headquartered in Wilmington, MA. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. It has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (“GLP”) and non-GLP. Charles River currently reports under three segments — Discovery and Safety Assessment (“DSA”), Research Models and Services (“RMS”) and Manufacturing Solutions.
Factors Favoring CRL’s Share Price Growth
Charles River’s share price is trending upward, prompted by strong DSA prospects. DSA’s organic revenue growth accelerated to 5.9% in the third quarter of 2026 from 0.2% in the second quarter. Net bookings rose 32% year over year to $652 million, while backlog increased to $2.03 billion. Net book-to-bill reached 1.09x, marking the fourth consecutive quarter above 1x and averaging approximately 1.1x over that period. Higher regulated safety assessment volumes, including nonhuman primate (NHP) studies and bioanalysis, supported the recovery.
Charles River’s divestiture of its CDMO and Cell Solutions businesses and certain European Discovery Services sites has sharpened the company’s investment focus on regulated testing and manufacturing quality control. The portfolio changes are also benefiting profitability.
Charles River’s gradual, long-term shift toward broader adoption of new approach methodologies looks encouraging. PathoQuest adds next-generation sequencing capabilities for in vitro testing, while its Arovella Therapeutics collaboration extends these capabilities into cell and gene therapy programs. The company also joined Eli Lilly's TuneLab initiative to contribute non-clinical expertise to AI-enabled drug discovery. Charles River introduced a new rapid cell banking program designed to reduce production timelines by 40% from the industry standard of 20 weeks.
From a solvency viewpoint, Charles River ended the third quarter of 2026 with $200.4 million in cash and cash equivalents compared with $192 million at the end of the second quarter. Long-term debt, net and finance leases totaled $2.44 billion, down from $2.62 billion in the second quarter. Management reported sequentially improved net leverage of 2.3x.
Image Source: Zacks Investment Research
Operating cash flow reached $474.9 million during the first nine months of 2026 compared with $590.1 million a year earlier. The company repurchased approximately $324 million of shares during the first nine months while funding strategic acquisitions and organic investments.
Factors That May Offset CRL’s Gains
Charles River's demand environment is recovering, but improvement remains uneven across client groups and end markets. RMS organic revenues declined 0.6%, driven by softer North American small-model demand and lower large-model shipments. With academic and government customers accounting for nearly 40% of RMS revenues, the segment remains exposed to ongoing budget uncertainty.
Also, the company’s revised 2026 outlook projects a 1.5% to 2.0% decline in reported revenues, despite expectations for organic revenue growth of at least 1.5%. The outlook includes an approximately 4.5% impact from divestitures and a favorable foreign-exchange contribution of 0.5% to 1.0%. Given Charles River's international operations, currency fluctuations remain a source of uncertainty for reported growth and period-to-period comparisons.
Estimates for CRL
The Zacks Consensus Estimate for 2026 earnings has moved north 0.4% to $11.41 in the past 30 days.
The company has an estimated long-term EPS growth rate of 12.4% compared with the industry’s 15.5% growth.
Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 43.3% compared with the industry’s 9.9% growth over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%.
Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4% compared with the industry’s 9.3%. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 59.6% compared with the industry’s 20.7% decline over the past year.
IDEXX Laboratories, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have risen 0.2% compared with the industry’s 2.4% growth over the past year.
Image: Bigstock
Charles River Stock Surges 102.3% in a Year: What's Fueling the Drive?
Key Takeaways
Charles River Laboratories International (CRL - Free Report) has witnessed strong momentum over the past year. Shares of the company have risen 102.3%, outperforming the industry’s 7.5% growth. The S&P 500 composite has increased 11.3% during the same time frame.
With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.
Charles River is a full-service, early-stage contract research organization, headquartered in Wilmington, MA. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. It has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (“GLP”) and non-GLP. Charles River currently reports under three segments — Discovery and Safety Assessment (“DSA”), Research Models and Services (“RMS”) and Manufacturing Solutions.
Factors Favoring CRL’s Share Price Growth
Charles River’s share price is trending upward, prompted by strong DSA prospects. DSA’s organic revenue growth accelerated to 5.9% in the third quarter of 2026 from 0.2% in the second quarter. Net bookings rose 32% year over year to $652 million, while backlog increased to $2.03 billion. Net book-to-bill reached 1.09x, marking the fourth consecutive quarter above 1x and averaging approximately 1.1x over that period. Higher regulated safety assessment volumes, including nonhuman primate (NHP) studies and bioanalysis, supported the recovery.
Charles River’s divestiture of its CDMO and Cell Solutions businesses and certain European Discovery Services sites has sharpened the company’s investment focus on regulated testing and manufacturing quality control. The portfolio changes are also benefiting profitability.
Charles River’s gradual, long-term shift toward broader adoption of new approach methodologies looks encouraging. PathoQuest adds next-generation sequencing capabilities for in vitro testing, while its Arovella Therapeutics collaboration extends these capabilities into cell and gene therapy programs. The company also joined Eli Lilly's TuneLab initiative to contribute non-clinical expertise to AI-enabled drug discovery. Charles River introduced a new rapid cell banking program designed to reduce production timelines by 40% from the industry standard of 20 weeks.
From a solvency viewpoint, Charles River ended the third quarter of 2026 with $200.4 million in cash and cash equivalents compared with $192 million at the end of the second quarter. Long-term debt, net and finance leases totaled $2.44 billion, down from $2.62 billion in the second quarter. Management reported sequentially improved net leverage of 2.3x.
Image Source: Zacks Investment Research
Operating cash flow reached $474.9 million during the first nine months of 2026 compared with $590.1 million a year earlier. The company repurchased approximately $324 million of shares during the first nine months while funding strategic acquisitions and organic investments.
Factors That May Offset CRL’s Gains
Charles River's demand environment is recovering, but improvement remains uneven across client groups and end markets. RMS organic revenues declined 0.6%, driven by softer North American small-model demand and lower large-model shipments. With academic and government customers accounting for nearly 40% of RMS revenues, the segment remains exposed to ongoing budget uncertainty.
Also, the company’s revised 2026 outlook projects a 1.5% to 2.0% decline in reported revenues, despite expectations for organic revenue growth of at least 1.5%. The outlook includes an approximately 4.5% impact from divestitures and a favorable foreign-exchange contribution of 0.5% to 1.0%. Given Charles River's international operations, currency fluctuations remain a source of uncertainty for reported growth and period-to-period comparisons.
Estimates for CRL
The Zacks Consensus Estimate for 2026 earnings has moved north 0.4% to $11.41 in the past 30 days.
The company has an estimated long-term EPS growth rate of 12.4% compared with the industry’s 15.5% growth.
Key Picks
Some better-ranked stocks in the broader medical space are Bausch + Lomb Corp. (BLCO - Free Report) , Insulet (PODD - Free Report) and IDEXX Laboratories (IDXX - Free Report) .
Bausch + Lomb has an estimated long-term growth rate of 40.1% compared with the industry’s 15.2% growth. Shares of the company have rallied 43.3% compared with the industry’s 9.9% growth over the past year. BLCO’s earnings outpaced estimates in two of the trailing four quarters, matched once and missed on another occasion, the average surprise being 21.67%.
BLCO sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Insulet, sporting a Zacks Rank #1, has an estimated long-term growth rate of 19.4% compared with the industry’s 9.3%. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.43%. PODD shares have dipped 59.6% compared with the industry’s 20.7% decline over the past year.
IDEXX Laboratories, currently carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.2% against the industry’s negative 2.3% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.5%. IDXX shares have risen 0.2% compared with the industry’s 2.4% growth over the past year.